This Article Full Text Full Text (PDF) All Versions of this Article: 147/7/3586    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sidis, Y. Articles by Schneyer, A. Search for Related Content PubMed PubMed Citation Articles by Sidis, Y. Articles by Schneyer, A.

Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins

Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Alan Schneyer, Ph.D., Reproductive Endocrine Unit BHX-5, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail Schneyer.alan{at}mgh.harvard.edu.

Follistatin (FST) and FST-like-3 (FSTL3) are activin-binding and neutralization proteins that also bind myostatin. Three FST isoforms have been described that differ in tissue distribution and cell-surface binding activity, suggesting that the FST isoforms and FSTL3 may have some nonoverlapping biological actions. We produced recombinant FST isoforms and FSTL3 and compared their biochemical and biological properties. Activin-binding affinities and kinetics were comparable between the isoforms and FSTL3, whereas cell-surface binding differed markedly (FST288 > FST303 > FST315 > FSTL3). Inhibition of endogenous activin bioactivity, whether the FST isoforms were administered endogenously or exogenously, correlated closely with surface binding activity, whereas neutralization of exogenous activin when FST and FSTL3 were also exogenous was consistent with their equivalent activin-binding affinities. This difference in activin inhibition was also evident in an in vitro bioassay because FST288 suppressed, whereas FST315 enhanced, activin-dependent TT cell proliferation. Moreover, when FSTL3, which does not associate with cell membranes, was expressed as a membrane-anchored protein, its endogenous activin inhibitory activity was dramatically increased. In competitive binding assays, myostatin was more potent than bone morphogenetic proteins (BMPs) 6 and 7, and BMPs 2 and 4 were inactive in binding to FST isoforms, whereas none of the BMPs tested competed with activin for binding to FSTL3. Neutralization of exogenous BMP or myostatin bioactivity correlated with the relative abilities of the isoforms to bind cell-surface proteoglycans. These results indicate that the differential biological actions among the FST isoforms and FSTL3 are primarily dependent on their relative cell-surface binding ability and ligand specificity.

This article has been cited by other articles:

				A. L. Schneyer, Y. Sidis, A. Gulati, J. L. Sun, H. Keutmann, and P. A. Krasney Differential Antagonism of Activin, Myostatin and Growth and Differentiation Factor 11 by Wild-Type and Mutant Follistatin Endocrinology, September 1, 2008; 149(9): 4589 - 4595. [Abstract] [Full Text] [PDF]

				G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF]

				Y. Xia, J. L. Babitt, Y. Sidis, R. T. Chung, and H. Y. Lin Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin Blood, May 15, 2008; 111(10): 5195 - 5204. [Abstract] [Full Text] [PDF]

				A. L. Blount, J. M. Vaughan, W. W. Vale, and L. M. Bilezikjian A Smad-binding Element in Intron 1 Participates in Activin-dependent Regulation of the Follistatin Gene J. Biol. Chem., March 14, 2008; 283(11): 7016 - 7026. [Abstract] [Full Text] [PDF]

				K Rae, K Hollebone, V Chetty, D Clausen, and J McFarlane Follistatin serum concentrations during full-term labour in women significant differences between spontaneous and induced labour Reproduction, November 1, 2007; 134(5): 705 - 711. [Abstract] [Full Text] [PDF]

				N. Antony, J. J. Bass, C. D. McMahon, and M. D. Mitchell Myostatin regulates glucose uptake in BeWo cells Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1296 - E1302. [Abstract] [Full Text] [PDF]

				A. Kashiwagi, C. M. DiGirolamo, Y. Kanda, Y. Niikura, C. T. Esmon, T. R. Hansen, T. Shioda, and J. K. Pru The Postimplantation Embryo Differentially Regulates Endometrial Gene Expression and Decidualization Endocrinology, September 1, 2007; 148(9): 4173 - 4184. [Abstract] [Full Text] [PDF]

				T. F. Lerch, S. Shimasaki, T. K. Woodruff, and T. S. Jardetzky Structural and Biophysical Coupling of Heparin and Activin Binding to Follistatin Isoform Functions J. Biol. Chem., May 25, 2007; 282(21): 15930 - 15939. [Abstract] [Full Text] [PDF]

				K. B Lee, V. Khivansara, M. M Santos, P. Lamba, T. Yuen, S. C Sealfon, and D. J Bernard Bone morphogenetic protein 2 and activin A synergistically stimulate follicle-stimulating hormone {beta} subunit transcription J. Mol. Endocrinol., February 1, 2007; 38(2): 315 - 330. [Abstract] [Full Text] [PDF]

				A. Mukherjee, Y. Sidis, A. Mahan, M. J. Raher, Y. Xia, E. D. Rosen, K. D. Bloch, M. K. Thomas, and A. L. Schneyer FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults PNAS, January 23, 2007; 104(4): 1348 - 1353. [Abstract] [Full Text] [PDF]

				T. Goswami and N. C. Andrews Hereditary Hemochromatosis Protein, HFE, Interaction with Transferrin Receptor 2 Suggests a Molecular Mechanism for Mammalian Iron Sensing J. Biol. Chem., September 29, 2006; 281(39): 28494 - 28498. [Abstract] [Full Text] [PDF]